Optimizing Mouse Models for Precision Cancer Prevention

Overview

Journal Nat Rev Cancer

Specialty Oncology

Date 2016 Feb 20

PMID 26893066

Citations 43

Authors

Clementine Le Magnen

Aditya Dutta

Cory Abate-Shen

Affiliations

Soon will be listed here.

Abstract

As cancer has become increasingly prevalent, cancer prevention research has evolved towards placing a greater emphasis on reducing cancer deaths and minimizing the adverse consequences of having cancer. 'Precision cancer prevention' takes into account the collaboration of intrinsic and extrinsic factors in influencing cancer incidence and aggressiveness in the context of the individual, as well as recognizing that such knowledge can improve early detection and enable more accurate discrimination of cancerous lesions. However, mouse models, and particularly genetically engineered mouse (GEM) models, have yet to be fully integrated into prevention research. In this Opinion article, we discuss opportunities and challenges for precision mouse modelling, including the essential criteria of mouse models for prevention research, representative success stories and opportunities for more refined analyses in future studies.

Citing Articles

Patient-derived xenograft model in cancer: establishment and applications.

Gu A, Li J, Li M, Liu Y MedComm (2020). 2025; 6(2):e70059.

PMID: 39830019 PMC: 11742426. DOI: 10.1002/mco2.70059.

NGF-mediated crosstalk: unraveling the influence of metabolic deregulation on the interplay between neural and pancreatic cancer cells and its impact on patient outcomes.

Trentini F, Agnetti V, Manini M, Giovannetti E, Garajova I Front Pharmacol. 2024; 15:1499414.

PMID: 39723256 PMC: 11668609. DOI: 10.3389/fphar.2024.1499414.

Esophageal adenocarcinoma models: a closer look.

Bhat N, Al-Mathkour M, Maacha S, Lu H, El-Rifai W, Ballout F Front Mol Biosci. 2024; 11:1440670.

PMID: 39600303 PMC: 11589788. DOI: 10.3389/fmolb.2024.1440670.

Emerging strategies to investigate the biology of early cancer.

Zhou R, Tang X, Wang Y Nat Rev Cancer. 2024; 24(12):850-866.

PMID: 39433978 DOI: 10.1038/s41568-024-00754-y.

Basal and Luminal Molecular Subtypes in Naturally-Occurring Canine Urothelial Carcinoma are Associated with Tumor Immune Signatures and Dog Breed.

Sommer B, Dhawan D, Ruple A, Ramos-Vara J, Hahn N, Utturkar S Bladder Cancer. 2024; 7(3):317-333.

PMID: 38993617 PMC: 11181872. DOI: 10.3233/BLC-201523.

References

Friedman A, Letai A, Fisher D, Flaherty K . Precision medicine for cancer with next-generation functional diagnostics. Nat Rev Cancer. 2015; 15(12):747-56. PMC: 4970460. DOI: 10.1038/nrc4015. View

Jordan V . Tamoxifen: a most unlikely pioneering medicine. Nat Rev Drug Discov. 2003; 2(3):205-13. DOI: 10.1038/nrd1031. View

Mou H, Kennedy Z, Anderson D, Yin H, Xue W . Precision cancer mouse models through genome editing with CRISPR-Cas9. Genome Med. 2015; 7(1):53. PMC: 4460969. DOI: 10.1186/s13073-015-0178-7. View

Hunter K . Mouse models of cancer: does the strain matter?. Nat Rev Cancer. 2012; 12(2):144-9. PMC: 6309955. DOI: 10.1038/nrc3206. View

Irshad S, Bansal M, Castillo-Martin M, Zheng T, Aytes A, Wenske S . A molecular signature predictive of indolent prostate cancer. Sci Transl Med. 2013; 5(202):202ra122. PMC: 3943244. DOI: 10.1126/scitranslmed.3006408. View

Daskivich T, Chamie K, Kwan L, Labo J, Palvolgyi R, Dash A . Overtreatment of men with low-risk prostate cancer and significant comorbidity. Cancer. 2011; 117(10):2058-66. DOI: 10.1002/cncr.25751. View

Donehower L, Harvey M, Slagle B, McArthur M, Montgomery Jr C, Butel J . Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature. 1992; 356(6366):215-21. DOI: 10.1038/356215a0. View

Shultz L, Brehm M, Garcia-Martinez J, Greiner D . Humanized mice for immune system investigation: progress, promise and challenges. Nat Rev Immunol. 2012; 12(11):786-98. PMC: 3749872. DOI: 10.1038/nri3311. View

Poruk K, Gay D, Brown K, Mulvihill J, Boucher K, Scaife C . The clinical utility of CA 19-9 in pancreatic adenocarcinoma: diagnostic and prognostic updates. Curr Mol Med. 2013; 13(3):340-51. PMC: 4419808. DOI: 10.2174/1566524011313030003. View

10.

Taguchi A, Politi K, Pitteri S, Lockwood W, Faca V, Kelly-Spratt K . Lung cancer signatures in plasma based on proteome profiling of mouse tumor models. Cancer Cell. 2011; 20(3):289-99. PMC: 3406925. DOI: 10.1016/j.ccr.2011.08.007. View

11.

Threadgill D, Miller D, Churchill G, Pardo-Manuel de Villena F . The collaborative cross: a recombinant inbred mouse population for the systems genetic era. ILAR J. 2011; 52(1):24-31. DOI: 10.1093/ilar.52.1.24. View

12.

Threadgill D, Churchill G . Ten years of the Collaborative Cross. Genetics. 2012; 190(2):291-4. PMC: 3276648. DOI: 10.1534/genetics.111.138032. View

13.

Green J, Hudson T . The promise of genetically engineered mice for cancer prevention studies. Nat Rev Cancer. 2005; 5(3):184-98. DOI: 10.1038/nrc1565. View

14.

Mayers J, Wu C, Clish C, Kraft P, Torrence M, Fiske B . Elevation of circulating branched-chain amino acids is an early event in human pancreatic adenocarcinoma development. Nat Med. 2014; 20(10):1193-1198. PMC: 4191991. DOI: 10.1038/nm.3686. View

15.

Hung K, Faca V, Song K, Sarracino D, Richard L, Krastins B . Comprehensive proteome analysis of an Apc mouse model uncovers proteins associated with intestinal tumorigenesis. Cancer Prev Res (Phila). 2009; 2(3):224-33. PMC: 2874864. DOI: 10.1158/1940-6207.CAPR-08-0153. View

16.

Cooperberg M, Carroll P, Klotz L . Active surveillance for prostate cancer: progress and promise. J Clin Oncol. 2011; 29(27):3669-76. DOI: 10.1200/JCO.2011.34.9738. View

17.

Collins F, Varmus H . A new initiative on precision medicine. N Engl J Med. 2015; 372(9):793-5. PMC: 5101938. DOI: 10.1056/NEJMp1500523. View

18.

Olive K, Politi K . Translational therapeutics in genetically engineered mouse models of cancer. Cold Spring Harb Protoc. 2014; 2014(2):131-43. DOI: 10.1101/pdb.top069997. View

19.

Kemp C . Animal Models of Chemical Carcinogenesis: Driving Breakthroughs in Cancer Research for 100 Years. Cold Spring Harb Protoc. 2015; 2015(10):865-74. PMC: 4949043. DOI: 10.1101/pdb.top069906. View

20.

Welch H, Black W . Overdiagnosis in cancer. J Natl Cancer Inst. 2010; 102(9):605-13. DOI: 10.1093/jnci/djq099. View